Cite This Page

Citation styles for Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective

APA style

Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective. (2024, January 25). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 16:19, June 16, 2024 from https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992.

MLA style

"Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 25 Jan 2024, 09:18 UTC. 16 Jun 2024, 16:19 <https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 25 January 2024, 09:18 UTC, <https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992> [accessed 16 June 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992 (accessed June 16, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 25, 09:18 UTC [cited 2024 Jun 16]. Available from: https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992.

Bluebook style

Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective, https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992 (last visited June 16, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992",
   note = "[Online; accessed 16-June-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred:

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Insight from the basic safety user profile associated with antidiabetic providers glucagonlike peptide1 agonists and dipeptidyl peptidase4 inhibitors inside daily practice through the individual perspective --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Insight_from_the_basic_safety_user_profile_associated_with_antidiabetic_providers_glucagonlike_peptide1_agonists_and_dipeptidyl_peptidase4_inhibitors_inside_daily_practice_through_the_individual_perspective&oldid=613992}",
   note = "[Online; accessed 16-June-2024]"
 }